JBM HEALTHCARE(02161) Earnings Summary
Bullish Points:
1. Revenue for the financial year 2023 increased by 28.1% to HKD 520.3 million.
2. Adjusted EBITDA grew by 36.2%, and net profit attributable to equity holders increased by 132.1%.
3. Strong growth in branded Chinese medicine sales, driven by increased demand for traditional Chinese medicine and concentrated Chinese medicine granules.
4. Strong performance in Oncotype DX breast cancer gene expression test.
5. Company focuses on expanding cross-border e-commerce business and exploring opportunities in the Greater Bay Area consumer healthcare market.
Bearish Points:
1. Slight decline in branded pharmaceuticals and health supplements sales.
2. Branded drugs division experienced a slight decline of 7.7%, mainly due to a decrease in sales of AIM Atropine eye drops.
3. Health supplements division sales slightly decreased by 6.2%, mainly due to reduced sales of some products in the Hong Kong retail market.
In summary, JBM Healthcare has shown strong growth in revenue and net profit for the financial year 2023, driven by increased demand for branded Chinese medicine and the expansion of cross-border e-commerce business. However, there were slight declines in branded pharmaceuticals and health supplements sales. The company is focusing on exploring opportunities in the Greater Bay Area consumer healthcare market to continue its growth. For more information, you can read the original text of JBM Healthcare's financial report: https://static.tigerbbs.com/90359ce4124b4dae8ba77d6d3260d25c
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
